• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Midatech Pharma PLC Announces Further re: Notice of General Meeting

    3/10/23 1:45:00 PM ET
    $MTP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTP alert in real time by email

    Midatech Pharma PLC ("Midatech" or the "Company") Further re: Notice of General Meeting - Correction of Typographical Errors

    ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 10, 2023 / Further to the announcement made on 8 March 2023 providing notice of a general meeting (the "GM") of the Company to be held on 24 March 2023, and the publication and despatch of a circular to shareholders containing notice of the resolutions to be considered at the GM (the "Notice") and form of proxy (the "Form of Proxy"), the Company announces the following corrections to certain typographical errors identified within the Notice and Form of Proxy:

    · Resolution 4 of the Notice ("Resolution 4") refers to a proposed authority to waive pre-emption rights in respect of the allotment authority sought by resolution 2 of the Notice which is limited to an aggregate nominal amount of £1,911,169.68. Accordingly, the waiver of pre-emption rights authority sought by Resolution 4 should be an amount of £1,911,169.68 (not £2,905,400.59 as currently stated in the Notice);

    · Resolution 5 of the Notice ("Resolution 5") refers to a proposed authority to waive pre-emption rights in respect of the allotment authority sought by resolution 3 of the Notice which is limited to an aggregate nominal amount of £2,300,000.00. Accordingly, the waiver of pre-emption rights authority sought by Resolution 5 should be an amount of £2,300,000.00 (not £4,200,000 as currently stated in the Notice); and

    · Resolution 4 as described on the Form of Proxy incorrectly states that it is "To authorise grant the Directors authority to allot shares in the Company in connection with the grant of the A Warrants, the B Warrants, the Ladenburg Warrants, the Waiver Warrants and the Pre-Funded Warrants" (which effectively duplicates resolution 2 of the Form of Proxy). In accordance with the resolutions set out in the Notice, resolution 4 of the Form of Proxy should instead state that it is "To disapply statutory pre-emption rights in connection with the grant of the A Warrants, the B Warrants, the Ladenburg Warrants, the Waiver Warrants and the Pre-Funded Warrants".

    As such errors are administrative in nature, no new Notice will be published and the aforementioned amendments to Resolution 4 and Resolution 5 will be effected by a motion to be passed at the GM. Furthermore, no new Form of Proxy will be posted to shareholders but a copy of the corrected Form of Proxy will be made available on the Company's website at: www.midatechpharma.com/. Any shareholder who wishes to change any proxy instructions already submitted may do so by submitting a new proxy appointment using the method set out in the notes to the Notice.

    For more information, please contact:Midatech Pharma PLC

    Stephen Stamp, CEO, CFO

    Tel: +44 (0)29 2048 0180

    www.midatechpharma.com


    Strand Hanson Limited (Nominated Adviser and Broker)

    James Dance / Matthew Chandler / Rob Patrick

    Tel: +44 (0)20 7409 3494


    IFC Advisory Limited (Financial PR and UK Investor Relations)

    Tim Metcalfe / Graham Herring

    Tel: +44 (0)20 3934 6630

    Email: [email protected]

    Edison Group (US Investor Relations)

    Alyssa Factor

    Tel: +1 (860) 573 9637

    Email: [email protected]

    This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

    SOURCE: Midatech Pharma PLC



    View source version on accesswire.com:
    https://www.accesswire.com/743184/Midatech-Pharma-PLC-Announces-Further-re-Notice-of-General-Meeting

    Get the next $MTP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTP
    SEC Filings

    See more
    • SEC Form 6-K filed by Midatech Pharma PLC American Depositary Shs

      6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      1/22/24 8:51:48 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Midatech Pharma PLC American Depositary Shs

      6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      12/29/23 12:10:19 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Midatech Pharma PLC American Depositary Shs

      424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

      12/26/23 4:53:52 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTP
    Leadership Updates

    Live Leadership Updates

    See more
    • Midatech Pharma PLC Announces Appointment of Nominated and Financial Adviser

      ABINGDON, UK / ACCESSWIRE / March 8, 2022 / Midatech Pharma PLC ((AIM:MTPH, NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicine, is pleased to announce the appointment of Strand Hanson Limited as the Company's Nominated and Financial Adviser with immediate effect.Turner Pope Investments (TPI) Ltd will be the Company's sole broker.For further information, please contact:Midatech Pharma PLCStephen Stamp, CEO, CFOTel: +44 (0) 29 2048 0180www.midatechpharma.com Strand Hanson Limited (Nominated and Financial Adviser)James Dance / Matthew Chandler / Rob PatrickTel: +44 (0)20 7409 3494 Turner Pope Investments (TPI) Ltd (Broker)Andre

      3/8/22 5:00:00 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Midatech Pharma PLC Announces Appointment of Chief Scientific Officer

      Midatech Pharma PLC ('Midatech' or the 'Company') Midatech Strengthens Management Team with Appointment of Dr. Dmitry Zamoryakhin as Chief Scientific OfficerABINGDON, OXFORDSHIRE / ACCESSWIRE / July 12, 2021 / Midatech Pharma PLC ((AIM:MTPH, NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces the appointment of Dr. Dmitry Zamoryakhin as Chief Scientific Officer, a non-board role, with immediate effect.Dr. Zamoryakhin has broad experience across all phases of development of drugs and medical devices, working with regulatory authorities including the EMA, FDA, PMDA, and NMPA. Most recently, he was Chief Medical Offic

      7/12/21 9:50:00 AM ET
      $MTP
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Midatech Pharma PLC American Depositary Shs (Amendment)

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      2/14/24 8:47:28 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Midatech Pharma PLC American Depositary Shs (Amendment)

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      2/14/24 2:42:24 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Midatech Pharma PLC American Depositary Shs (Amendment)

      SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

      2/14/24 2:14:48 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Midatech Pharma PLC Announces R&D Programme Focused on Leptomeningeal Disease

      ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 27, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, is pleased to announce a new research programme coded MTD217 focusing on developing new therapeutic options for metastatic cancers with high unmet needs.BackgroundMany cancers exhibit high levels of metabolic plasticity, i.e. the ability to switch between energy-generating pathways in response to cellular stresses[1], such as those caused by chemotherapy. Highly proliferative cancers frequently use the aerobic glycolysis pathway, known as "the Warburg effect", to generate energy2. Oxidat

      3/27/23 8:20:00 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Midatech Pharma PLC Announces Results of General Meeting

      Share Consolidation, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIMABINGDON, OXFORDSHIRE / ACCESSWIRE / March 24, 2023 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that at the general meeting of the Company held earlier today (the "General Meeting"), all resolutions put to the Company's shareholders ("Shareholders") were duly passed.The full text of, inter alia, the resolutions proposed and passed at the General Meeting can be found in the Company's Shareholder Circular and Notice of General Meeting (the "Circular") which

      3/24/23 8:00:00 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Midatech Pharma PLC Announces Further re: Notice of General Meeting

      Midatech Pharma PLC ("Midatech" or the "Company") Further re: Notice of General Meeting - Correction of Typographical ErrorsABINGDON, OXFORDSHIRE / ACCESSWIRE / March 10, 2023 / Further to the announcement made on 8 March 2023 providing notice of a general meeting (the "GM") of the Company to be held on 24 March 2023, and the publication and despatch of a circular to shareholders containing notice of the resolutions to be considered at the GM (the "Notice") and form of proxy (the "Form of Proxy"), the Company announces the following corrections to certain typographical errors identified within the Notice and Form of Proxy:· Resolution 4 of the Notice ("Resolution 4") refers to a proposed aut

      3/10/23 1:45:00 PM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTP
    Financials

    Live finance-specific insights

    See more
    • Midatech Pharma PLC Announces Posting of Circular and Notice of General Meeting

      Proposed Share Consolidation, Authority to Allot Shares, Disapplication of Pre-Emption Rights, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIMABINGDON, OXFORDSHIRE / ACCESSWIRE / March 8, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces, further to the Company's announcements of 9 February and 15 February 2023, that a circular (the "Circular") and formal Notice of General Meeting was posted to shareholders yesterday and will be made available on the Company's website at: www.midatechpharma.com/investors/shareholder-information.The

      3/8/23 2:20:00 AM ET
      $MTP
      Biotechnology: Pharmaceutical Preparations
      Health Care